---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-014147"
form_type: "8-K"
ticker: "GOVX"
cik: "0000832489"
company_name: "GeoVax Labs, Inc."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T01:33:03.303297+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# GeoVax Q1 net loss narrows to $5.4M; BARDA award ended, COVID vaccine data due Q2 2025

## Summary
- Net loss $5.4M (vs $5.9M Q1 2024); revenue $1.6M from BARDA contract (none prior year).
- Cash $7.4M at Mar 31, 2025, up from $5.5M at Dec 31, 2024.
- BARDA Project NextGen award terminated unexpectedly; GEO-CM04S1 COVID vaccine continues.
- Healthy adult booster data for GEO-CM04S1 expected Q2 2025; GEO-MVA trial starts H2 2025.
- Gedeptin advancing to Phase 2 for recurrent head/neck cancer with checkpoint inhibitor.

## SEC filing metadata
- accession: 0001437749-25-014147
- form_type: 8-K
- ticker: GOVX
- cik: 0000832489
- company_name: GeoVax Labs, Inc.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/832489/000143774925014147/0001437749-25-014147-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/832489/000143774925014147/govx20250430_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-014147
- JSON: https://secwatch.observer/filing/0001437749-25-014147.json
- Plain text: https://secwatch.observer/filing/0001437749-25-014147.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.